Opendata, web and dolomites

variaTECT SIGNED

A novel genetic assay for risk assessment of cognitive decline in Alzheimer’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 variaTECT project word cloud

Explore the words cloud of the variaTECT project. It provides you a very rough idea of what is the project "variaTECT" about.

living    nucleotide    plasma    snpfitr    primary    dna    fluid    snpfitrtm    collected    deployment    tests    innovation    extracted    polymorphism    46m    cerebrospinal    10k    positron    2030    alzheimer    double    market    obtain    person    capacity    subjects    feasibility    genetic    unresolved    mark    array    prevalent    aging    pieces    initiated    vitro    lumbar    saliva    scans    platform    snp    degeneration    software    score    ce    emission    puncture    probability    accuracy    cytox    processed    tomography    csf    10m    detection    chain    disorder    provides    triple    beta    types    single    device    supply    variatect    upgrade    accurate    dementia    labs    strategy    plan    solutions    fast    drafted    2050    generate    save    individuals    broad    130k    stratify    trials    diagnostic    figure    data    progressively    worldwide    brain    blood    pet    almost    patient    cognitive    85    ad    leads    healthcare    people    complete    proprietary    risk    dysfunction    population    multiple    revenues    snps    clinical    amyloid    disease    ivd   

Project "variaTECT" data sheet

The following table provides information about the project.

Coordinator
CYTOX LIMITED 

Organization address
address: 53 FOUNTAIN STREET
city: MANCHESTER
postcode: M2 2AN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.cytoxgroup.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYTOX LIMITED UK (MANCHESTER) coordinator 50˙000.00

Map

 Project objective

Alzheimer’s Disease (AD) is the most prevalent cognitive disorder and progressively leads to complete brain dysfunction and degeneration. The number of people living with Alzheimer’s worldwide is now estimated at 46M, with this figure set to almost double by 2030 and more than triple by 2050 due to population aging. Current methods for early assessment of AD are based on detection of β-amyloid in the brain Positron Emission Tomography (PET) scans, blood plasma tests or in cerebrospinal fluid (CSF) (via lumbar puncture). However, these solutions present some unresolved issues for broad market deployment. Cytox has developed the variaTECT platform to stratify AD risk in individuals by using a fast, accurate, reliable and cost-effective way to generate specific genetic information. The variaTECT comprises a proprietary 130K single nucleotide polymorphism (SNP) variaTECT array and the proprietary SNPfitRTM software to analyse data generated from the array. DNA extracted from a patient’s blood or saliva sample is collected and analyzed on the variaTECT array. The primary genetic data are then processed by the SNPfitR software, which provides a risk score associated with the probability to develop AD. variaTECT has an 85% accuracy, it can save up to €10k person-year for the healthcare systems and it can generate new revenues (up to €10M) for genetic labs. During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. During the second phase of innovation project, Cytox will upgrade the array design to increase the number of SNPs and the SNPfitR software to stratify subjects into different dementia types. Production capacity will be increased up to 100,000 pieces per year. Multiple clinical trials will be then initiated to obtain CE mark as In-Vitro Diagnostic (IVD) device.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VARIATECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VARIATECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More